AB0016 HEPATITIS B SEROPREVALENCE AND REACTIVATION FREQUENCY IN PATIENTS USING BIOLOGICAL DRUGS OTHER THAN RITUXIMAB; SINGLE CENTER RESULTS

Background Biological drugs target immune or genetic mediators and are important treatment alternatives in rheumatology, especially patients with inadequate response to the conventional treatment. Hepatitis B reactivation may emerge during use of these agents. There is a higher risk rituximab (RTX) therapy. The frequency hepatitis non-RTX biologics unclear. Objectives seroprevalence were evaluated followed Kocaeli University Faculty Medicine rheumatology outpatient clinic treated biological drugs. Methods HBsAg, anti-HBs, anti-HBcIgG data 170 who received drug therapy for different indications between 2010 2022 analyzed retrospectively. HBV DNA PCR, liver enzyme elevation HBeAg reversion reactivation, HBsAg positive patients. divided into 5 groups as (+) (Group 1), (-), anti-HBs 2), anti-HBc IgG 3), whole serology negative 4) vaccine-immunized 5). Results mean age study population was 47.4±10.6 years. 57.6% ankylosing spondylitis (AS), 24.1% rheumatoid arthritis, 8.8% psoriatic arthritis. Behçet’s disease Takayasu arteritis observed 3.5% 2.4% patients, respectively. consisting various rheumatological diseases including Familial Mediterranean fever, giant cell arteritis, adult Still’s disease. In anti-tumor necrosis factor (TNF) non-TNF (tocilizumab, abatacept, secukinumab) 80% 20%, Most group 4 (n=114, 67.1%). distribution based on shown Table 1. 1 receiving antiviral Other did not receive any 3, patient up diagnosis AS infliximab After this started take which classified 1, non-significant increase viral load (<1 log10 IU/mL) revealed. However, we consider had due normal level enzymes absence reversion. Conclusion Patients using treatments have medium terms reactivation. usage prophylaxis quite low. our study, less. On other hand, should be carefully screened order prevent Data Receiving Non-Rituximab Treatment N(%) Gender Female 79(46,5) Male 91(53,5) Diagnosis Rheumatoid Arthritis 41(24,1) Ankylosing 98(57,6) Psoriatic 15(8,8) Behcet ‘s 6(3,5) 4(2,4) Groups by Viral Markers Group - 5(2,9) 2 (+), 13(7,6) 3 14(8,2) (-) 114(67,1) 24(14,1) Reactivation Rate 1(7,1) REFERENCES: NIL. Acknowledgements: Disclosure Interests None Declared.